Related Experiment Video
Updated: Sep 30, 2025

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
IL-6 Prevents Lung Macrophage Death and Lung Inflammation Injury by Inhibiting GSDME- and GSDMD-Mediated Pyroptosis
Xuemei Gou1,2, Wenchun Xu1, Yusi Liu3
1Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
Abstract:
Streptococcus pneumoniae is a leading bacterial cause of a wide range of infections, and pneumococcal pneumosepsis causes high mortality in hosts infected with antibiotic-resistant strains and those who cannot resolve ongoing inflammation. The factors which influence the development and outcome of pneumosepsis are currently unclear. IL-6 is critical for maintaining immune homeostasis, and we determined that this cytokine is also essential for resisting pneumosepsis, as it inhibits macrophage pyroptosis and pyroptosis-related inflammation injury in the lung. IL-6 affected infection outcomes in mice and exerted a protective role, primarily via macrophages. We further found that IL-6 deficiency led to increased lung macrophage death and aggravated lung inflammation, and that exogenous administration of IL-6 protein could decrease macrophage death and alleviate lung tissue inflammation. IL-6 also protected Streptococcus pneumoniae-induced lung macrophage death and lung inflammation injury by inhibiting gasdermin E (GSDME)- and gasdermin D (GSDMD)-mediated pyroptosis. Together, these data reveal a novel mechanism for the development of pneumosepsis and the critical protective role of IL-6. These findings may assist in the early identification and treatment of pneumococcal pneumosepsis. IMPORTANCE Pneumococcal pneumonia has been a significant cause of morbidity and mortality throughout human history. Failing to control pneumococcal pneumonia and resolve ongoing inflammation in a host can cause sepsis, namely pneumococcal pneumosepsis, and death ensues. Few theories have suggested an optimally therapeutic option for this infectious disease. The interleukin-6 (IL-6, a cytokine featuring pleiotropic activity) theory, proposed here, implies that IL-6 acts as a protector against pneumococcal pneumosepsis. IL-6 prevents lung macrophage death and lung inflammation injury by inhibiting a caspase-3-GSDME-mediated switch from apoptosis to pyroptosis and inhibiting caspase-1-GSDMD-mediated classic pyroptosis during pneumococcal pneumosepsis. Thus, IL-6 is an important determinant for controlling bacterial invasion and a homeostatic coordinator of pneumococcal pneumosepsis. This study clarifies a novel mechanism of occurrence and development of pneumonia and secondary sepsis following a Streptococcus pneumoniae infection. It is important for the early identification and treatment of pneumococcal pneumosepsis.
Insights
Interleukin-6 (IL-6) protects against pneumococcal pneumosepsis by preventing lung macrophage death and inflammation. This discovery offers a new therapeutic target for this severe bacterial infection.
Area of Science:
- Immunology and Infectious Diseases
- Cellular Biology and Inflammation
Background:
- Streptococcus pneumoniae causes severe infections, including pneumococcal pneumosepsis, leading to high mortality, especially in antibiotic-resistant cases.
- The mechanisms driving pneumosepsis development and outcomes, particularly unresolved inflammation, remain unclear.
- Interleukin-6 (IL-6) is crucial for immune homeostasis but its role in pneumosepsis was not fully understood.
Purpose of the Study:
- To investigate the role of IL-6 in resisting pneumococcal pneumosepsis and its impact on macrophage pyroptosis and lung inflammation.
- To elucidate the protective mechanisms of IL-6 against Streptococcus pneumoniae-induced lung injury.
Main Methods:
- Utilized a mouse model of Streptococcus pneumoniae infection to assess IL-6's influence on infection outcomes.
- Examined the effects of IL-6 deficiency and exogenous IL-6 administration on lung macrophage death and inflammation.
- Investigated IL-6's inhibition of gasdermin E (GSDME)- and gasdermin D (GSDMD)-mediated pyroptosis in macrophages.
Main Results:
- IL-6 demonstrated a critical protective role against pneumosepsis, primarily by acting on macrophages.
- IL-6 deficiency resulted in increased lung macrophage death and exacerbated lung inflammation.
- Exogenous IL-6 administration reduced macrophage death and alleviated lung inflammation, inhibiting GSDME- and GSDMD-mediated pyroptosis.
Conclusions:
- IL-6 is essential for resisting pneumococcal pneumosepsis by inhibiting macrophage pyroptosis and subsequent lung inflammation.
- This study reveals a novel mechanism for pneumosepsis development and highlights IL-6's protective function.
- Findings support IL-6 as a potential therapeutic target for early identification and treatment of pneumococcal pneumosepsis.

